Literature DB >> 22876029

Crucial steps in the natural history of inflammatory bowel disease.

Giovanni Latella1, Claudio Papi.   

Abstract

Inflammatory bowel diseases (IBD), including ulcerative colitis (UC) and Crohn's disease (CD), are chronic, progressive and disabling disorders. Over the last few decades, new therapeutic approaches have been introduced which have led not only to a reduction in the mortality rate but also offered the possibility of a favorable modification in the natural history of IBD. The identification of clinical, genetic and serological prognostic factors has permitted a better stratification of the disease, thus allowing the opportunity to indicate the most appropriate therapy. Early treatment with immunosuppressive drugs and biologics has offered the opportunity to change, at least in the short term, the course of the disease by reducing, in a subset of patients with IBD, hospitalization and the need for surgery. In this review, the crucial steps in the natural history of both UC and CD will be discussed, as well as the factors that may change their clinical course. The methodological requirements for high quality studies on the course and prognosis of IBD, the true impact of environmental and dietary factors on the clinical course of IBD, the clinical, serological and genetic predictors of the IBD course (in particular, which of these are relevant and appropriate for use in clinical practice), the impact of the various forms of medical treatment on the IBD complication rate, the role of surgery for IBD in the biologic era, the true magnitude of risk of colorectal cancer associated with IBD, as well as the mortality rate related to IBD will be stressed; all topics that are extensively discussed in separate reviews included in this issue of World Journal of Gastroenterology.

Entities:  

Keywords:  Clinical course; Complications; Crohn’s disease; Inflammatory bowel disease; Mortality; Natural history; Surgery; Therapy; Ulcerative colitis

Mesh:

Year:  2012        PMID: 22876029      PMCID: PMC3413049          DOI: 10.3748/wjg.v18.i29.3790

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  114 in total

1.  The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management.

Authors:  A Dignass; G Van Assche; J O Lindsay; M Lémann; J Söderholm; J F Colombel; S Danese; A D'Hoore; M Gassull; F Gomollón; D W Hommes; P Michetti; C O'Morain; T Oresland; A Windsor; E F Stange; S P L Travis
Journal:  J Crohns Colitis       Date:  2010-01-15       Impact factor: 9.071

2.  Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology.

Authors:  Mark S Silverberg; Jack Satsangi; Tariq Ahmad; Ian D R Arnott; Charles N Bernstein; Steven R Brant; Renzo Caprilli; Jean-Frédéric Colombel; Christoph Gasche; Karel Geboes; Derek P Jewell; Amir Karban; Edward V Loftus; A Salvador Peña; Robert H Riddell; David B Sachar; Stefan Schreiber; A Hillary Steinhart; Stephan R Targan; Severine Vermeire; B F Warren
Journal:  Can J Gastroenterol       Date:  2005-09       Impact factor: 3.522

Review 3.  Enteral nutritional therapy for induction of remission in Crohn's disease.

Authors:  M Zachos; M Tondeur; A M Griffiths
Journal:  Cochrane Database Syst Rev       Date:  2007-01-24

4.  In favour of early surgery in Crohn's disease: a hypothesis to be tested.

Authors:  Giovanni Latella; Renzo Caprilli; Simon Travis
Journal:  J Crohns Colitis       Date:  2010-12-13       Impact factor: 9.071

Review 5.  Impact of environmental and dietary factors on the course of inflammatory bowel disease.

Authors:  Eduard Cabré; Eugeni Domènech
Journal:  World J Gastroenterol       Date:  2012-08-07       Impact factor: 5.742

6.  The risk of colorectal cancer in ulcerative colitis: a meta-analysis.

Authors:  J A Eaden; K R Abrams; J F Mayberry
Journal:  Gut       Date:  2001-04       Impact factor: 23.059

Review 7.  Inflammatory bowel disease: Established and evolving considerations on its etiopathogenesis and therapy.

Authors:  Anja Schirbel; Claudio Fiocchi
Journal:  J Dig Dis       Date:  2010-10       Impact factor: 2.325

8.  Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.

Authors:  Stephen B Hanauer; Brian G Feagan; Gary R Lichtenstein; Lloyd F Mayer; S Schreiber; Jean Frederic Colombel; Daniel Rachmilewitz; Douglas C Wolf; Allan Olson; Weihang Bao; Paul Rutgeerts
Journal:  Lancet       Date:  2002-05-04       Impact factor: 79.321

Review 9.  Medical therapy for Crohn's disease strictures.

Authors:  Gert Van Assche; Karel Geboes; Paul Rutgeerts
Journal:  Inflamm Bowel Dis       Date:  2004-01       Impact factor: 5.325

10.  Clostridium difficile Infection and Inflammatory Bowel Disease: A Review.

Authors:  Preetika Sinh; Terrence A Barrett; Laura Yun
Journal:  Gastroenterol Res Pract       Date:  2011-09-12       Impact factor: 2.260

View more
  37 in total

1.  Role of Salmonella enterica exposure in Chilean Crohn's disease patients.

Authors:  Manuel Alvarez-Lobos; Daniela P Pizarro; Christian E Palavecino; Abner Espinoza; Valentina P Sebastián; Juan C Alvarado; Patricio Ibañez; Carlos Quintana; Orlando Díaz; Alexis M Kalergis; Susan M Bueno
Journal:  World J Gastroenterol       Date:  2013-09-21       Impact factor: 5.742

2.  IL-17A Promotes Initiation and Development of Intestinal Fibrosis Through EMT.

Authors:  Hui-Jing Zhang; Yi-Ning Zhang; Huan Zhou; Lin Guan; Yue Li; Ming-Jun Sun
Journal:  Dig Dis Sci       Date:  2018-08-10       Impact factor: 3.199

Review 3.  Cytokine and anti-cytokine therapies in prevention or treatment of fibrosis in IBD.

Authors:  Noam Jacob; Stephan R Targan; David Q Shih
Journal:  United European Gastroenterol J       Date:  2016-05-10       Impact factor: 4.623

Review 4.  Crohn's Disease: Evolution, Epigenetics, and the Emerging Role of Microbiome-Targeted Therapies.

Authors:  Ersilia M DeFilippis; Randy Longman; Michael Harbus; Kyle Dannenberg; Ellen J Scherl
Journal:  Curr Gastroenterol Rep       Date:  2016-03

Review 5.  The Natural History of IBD: Lessons Learned.

Authors:  Petra Weimers; Pia Munkholm
Journal:  Curr Treat Options Gastroenterol       Date:  2018-03

6.  JAK2 rs10758669 polymorphisms and susceptibility to ulcerative colitis and Crohn's disease: a meta-analysis.

Authors:  Ji-Xiang Zhang; Jia Song; Jun Wang; Wei-Guo Dong
Journal:  Inflammation       Date:  2014-06       Impact factor: 4.092

Review 7.  Novel biomarkers of fibrosis in Crohn's disease.

Authors:  Gianluca Pellino; Pierlorenzo Pallante; Francesco Selvaggi
Journal:  World J Gastrointest Pathophysiol       Date:  2016-08-15

Review 8.  Anti-TNF alpha in the treatment of ulcerative colitis: a valid approach for organ-sparing or an expensive option to delay surgery?

Authors:  Gianluca Rizzo; Daniela Pugliese; Alessandro Armuzzi; Claudio Coco
Journal:  World J Gastroenterol       Date:  2014-05-07       Impact factor: 5.742

9.  The Intersection of TNF, IBD and the Microbiome.

Authors:  Yava L Jones-Hall; Cindy H Nakatsu
Journal:  Gut Microbes       Date:  2016

Review 10.  Dysregulation of mucosal immune response in pathogenesis of inflammatory bowel disease.

Authors:  Xiao-Rong Xu; Chang-Qin Liu; Bai-Sui Feng; Zhan-Ju Liu
Journal:  World J Gastroenterol       Date:  2014-03-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.